Table 1.

Study cohort characteristics (n = 44)

Sex
 Men23 (52%)
 Women21 (48%)
Median age in years (range)a63 (32–89)
Ethnicity
 Caucasian38 (86%)
 Hispanic3 (7%)
 Asian2 (5%)
 Other1 (2%)
Malignancy
 Adenoid cystic carcinoma1 (2%)
 Appendiceal carcinoma1 (2%)
 Basal cell carcinoma2 (5%)
 Bladder urothelial carcinoma2 (5%)
 Breast cancer4 (9%)
 Cervical cancer1 (2%)
 Colorectal adenocarcinoma2 (5%)
 Cutaneous squamous cell carcinoma2 (5%)
 Soft-tissue sarcoma3 (7%)
 Gastroesophageal cancer3 (7%)
 Glioblastoma1 (2%)
 Head and neck squamous cell carcinoma1 (2%)
 Hepatocellular carcinoma2 (5%)
 Melanoma8 (18%)
 Neuroendocrine tumor1 (1%)
 Non–small cell lung cancer8 (18%)
 Ovarian cancer1 (2%)
 Thyroid cancer1 (2%)
Disease status at time of treatment and cell-free DNA collection
 Locally advanced disease6 (14%)
 Metastatic disease38 (86%)
Treatment
 Median number of prior systemic treatments (range)2 (0–5)
 Nivolumab16 (36%)
 Pembrolizumab19 (43%)
 Atezolizumab3 (7%)
 Nivolumab + ipilimumab3 (7%)
 Nivolumab + targeted therapy2 (5%)
 Nivolumab + chemotherapy1 (2%)
PFS in months: median (range)b2.8 (0.1–18.4+)
  • aPatient's age is at the time of immunotherapy treatment and cfDNA collection.

  • bCalculated using the method of Kaplan and Meier.